Pseudomyxoma Peritonei — Research Summary
Printed from RareWays (rareways.com.au) on 18 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Surgical outcomes of appendiceal mucinous neoplasms: A systematic review and meta-analysis.
Tang Phuong Minh et al. — Surgical oncology (4 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42704973/
- 2.
Clinical Outcomes of Low-Grade Appendiceal Mucinous Neoplasms in a Single Institution.
Nakagawa Yutaro et al. — The Kurume medical journal (31 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42669469/
- 3.
Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.
Sugarbaker Paul H et al. — Journal of surgical oncology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42098056/
- 4.
Prognostic ceiling effect of the Peritoneal Cancer Index in super-extended pseudomyxoma peritonei of appendiceal origin: impact of anatomical disease distribution and surgical complexity.
D'Annibale Giorgio et al. — Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42150629/
- 5.
Quality of life in patients with pseudomyxoma peritonei treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and implications for ERAS-informed rehabilitation.
Wang Shu-Li et al. — European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42247962/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Pseudomyxoma Peritonei
Pseudomyxoma peritonei is a rare condition in which mucus-producing tumour cells, usually starting in the appendix, spread within the abdomen and build up as thick jelly-like fluid. This can press on the bowel and other organs, causing swelling, pain and bowel problems. Standard care is major surgery to remove the disease combined with heated chemotherapy into the abdomen, followed by long-term monitoring.
Most Recent Research
PURPOSE: Appendiceal mucinous neoplasms are rare tumors with heterogeneous pathology, typically treated with appendectomy, cecectomy, right hemicolectomy, or cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Survival outcomes across surgical approaches remain unclear. We evaluated the outcomes of all surgical interventions for appendiceal mucinous neoplasms. METHODS: Eligible randomized controlled trials and cohort studies were retrieved from Cochrane, PubMed, Embase, and Scopus to August, 2026. Outcomes included overall and disease-free survival, recurrence, lymph-node positivity, and postoperative complications. Random-effects models were used to pool estimates. Certainty was appraised with GRADE. RESULTS: The review included 43 observational cohort studies involving 12,014 patients. In localized appendiceal mucinous neoplasms, recurrence was 1.4% after appendectomy and 2.3% after right hemicolectomy. In pseudomyxoma peritonei with CRS + HIPEC, 30- and 90-day mortality was 1.8% and 1.8%. Five-year overall survival was 94.2%, 78.1%, and 47.4% for acellular mucin, low-grade, and high-grade cohorts; 5-year disease-free survival was 92.8%, 56.9%, and 30%. High-grade disease was associated with worse overall survival (hazard ratio (HR), 3.19; 95% confidence interval (CI), 1.88-5.41) and disease-free survival (HR, 3.06; 95% CI, 1.68-5.58). Incomplete cytoreduction was associated with worse overall survival (HR, 3.39; 95% CI, 1.54-7.45). CONCLUSIONS: In localized appendiceal mucinous neoplasms, recurrence after resection is low; nodal involvement is uncommon in low-grade lesions but more frequently observed in mucinous adenocarcinoma. In pseudomyxoma peritonei, long-term survival after CRS + HIPEC varies by histologic grade and cytoreductive completeness. These factors may inform counseling, operative planning, and surveillance, but findings require cautious interpretation given low or very low certainty.
Common Questions
What is Pseudomyxoma Peritonei?
Pseudomyxoma peritonei is a rare condition in which mucus-producing tumour cells, usually starting in the appendix, spread within the abdomen and build up as thick jelly-like fluid. This can press on the bowel and other organs, causing swelling, pain and bowel problems. Standard care is major surgery to remove the disease combined with heated chemotherapy into the abdomen, followed by long-term monitoring.
How many clinical trials are available for Pseudomyxoma Peritonei?
RareWays currently indexes 25 clinical trials for Pseudomyxoma Peritonei, of which 10 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Pseudomyxoma Peritonei come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Pseudomyxoma Peritonei.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.